AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
19.43
-0.15 (-0.77%)
May 9, 2025, 12:57 PM - Market open

AnaptysBio Statistics

Total Valuation

AnaptysBio has a market cap or net worth of $570.86 million. The enterprise value is $593.63 million.

Market Cap 570.86M
Enterprise Value 593.63M

Important Dates

The last earnings date was Monday, May 5, 2025, after market close.

Earnings Date May 5, 2025
Ex-Dividend Date n/a

Share Statistics

AnaptysBio has 29.38 million shares outstanding. The number of shares has increased by 10.16% in one year.

Current Share Class 29.38M
Shares Outstanding 29.38M
Shares Change (YoY) +10.16%
Shares Change (QoQ) +0.64%
Owned by Insiders (%) 2.20%
Owned by Institutions (%) 89.90%
Float 16.76M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 5.14
Forward PS 16.54
PB Ratio 17.49
P/TBV Ratio 17.27
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 5.31
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.25, with a Debt / Equity ratio of 10.17.

Current Ratio 8.25
Quick Ratio 8.13
Debt / Equity 10.17
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -1.62

Financial Efficiency

Return on equity (ROE) is -343.83% and return on invested capital (ROIC) is -16.60%.

Return on Equity (ROE) -343.83%
Return on Assets (ROA) -15.14%
Return on Invested Capital (ROIC) -16.60%
Return on Capital Employed (ROCE) -26.53%
Revenue Per Employee $822,588
Profits Per Employee -$1.03M
Employee Count 136
Asset Turnover 0.27
Inventory Turnover n/a

Taxes

In the past 12 months, AnaptysBio has paid $47,000 in taxes.

Income Tax 47,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -24.19% in the last 52 weeks. The beta is -0.20, so AnaptysBio's price volatility has been lower than the market average.

Beta (5Y) -0.20
52-Week Price Change -24.19%
50-Day Moving Average 18.48
200-Day Moving Average 24.03
Relative Strength Index (RSI) 48.49
Average Volume (20 Days) 580,478

Short Selling Information

The latest short interest is 10.77 million, so 36.65% of the outstanding shares have been sold short.

Short Interest 10.77M
Short Previous Month 10.73M
Short % of Shares Out 36.65%
Short % of Float 64.25%
Short Ratio (days to cover) 10.93

Income Statement

In the last 12 months, AnaptysBio had revenue of $111.87 million and -$140.62 million in losses. Loss per share was -$4.79.

Revenue 111.87M
Gross Profit -56.11M
Operating Income -100.29M
Pretax Income -170.11M
Net Income -140.62M
EBITDA -99.70M
EBIT -100.29M
Loss Per Share -$4.79
Full Income Statement

Balance Sheet

The company has $339.94 million in cash and $345.96 million in debt, giving a net cash position of -$6.02 million or -$0.20 per share.

Cash & Cash Equivalents 339.94M
Total Debt 345.96M
Net Cash -6.02M
Net Cash Per Share -$0.20
Equity (Book Value) 34.02M
Book Value Per Share 1.12
Working Capital 319.08M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$108.78 million and capital expenditures -$366,000, giving a free cash flow of -$109.15 million.

Operating Cash Flow -108.78M
Capital Expenditures -366,000
Free Cash Flow -109.15M
FCF Per Share -$3.72
Full Cash Flow Statement

Margins

Gross margin is -50.15%, with operating and profit margins of -89.64% and -125.70%.

Gross Margin -50.15%
Operating Margin -89.64%
Pretax Margin -125.66%
Profit Margin -125.70%
EBITDA Margin -89.12%
EBIT Margin -89.64%
FCF Margin n/a

Dividends & Yields

AnaptysBio does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -10.16%
Shareholder Yield -10.16%
Earnings Yield -23.93%
FCF Yield -18.58%

Analyst Forecast

The average price target for AnaptysBio is $37.75, which is 94.29% higher than the current price. The consensus rating is "Buy".

Price Target $37.75
Price Target Difference 94.29%
Analyst Consensus Buy
Analyst Count 10
Revenue Growth Forecast (5Y) 11.02%
EPS Growth Forecast (5Y) 0.79%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

AnaptysBio has an Altman Z-Score of -1.15 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.15
Piotroski F-Score 3